GLP-1 and Medical Weight Loss: How the Ozempic Era Is Reshaping Med Spa Valuations

Three years ago, “medical weight loss” in the med spa context meant phentermine, B12 shots, and nutrition counseling. The total addressable market was modest. The buyer universe was small. Most M&A advisors didn’t have a strong opinion about it.

Then GLP-1s landed. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) reshaped the entire medical weight loss segment in less than 36 months. The patient base exploded, the unit economics changed, the regulatory landscape complicated, and the buyer universe started forming in real time.

This post is what we know about how GLP-1s have changed med spa valuations — and what it means for owners with weight loss programs in their practices today.

The GLP-1 Shift

GLP-1 drugs have expanded medical-weight-loss demand and created new diligence questions for clinics. Practice-level growth, patient retention, margins, and buyer interest vary materially and should be supported by the clinic’s own records rather than generalized revenue or transaction benchmarks.

How Buyers Evaluate GLP-1 Revenue

Buyers may examine collected revenue, patient retention, medication and clinical labor cost, refund exposure, prescribing continuity, vendor concentration, and the durability of the program under different supply and pricing conditions. No universal patient-revenue, retention, margin, or valuation benchmark applies.

The compounding question

For practices that built their model on compounded semaglutide or tirzepatide during the FDA shortage period, the regulatory landscape is the central question buyers ask. Compounding pharmacies were able to produce semaglutide and tirzepatide as long as the branded products were on the FDA shortage list. When the shortage status changed, the legal framework for compounding these products changed with it.

Buyers underwrite this risk by asking:

• How are you sourcing currently? Compounded, branded, or hybrid?
• What is your sterility and quality control process? Which pharmacy partners do you use, and what is their compliance record?
• What is your transition plan if compounding access narrows further? Do you have a path to branded GLP-1s, and what would that do to your margins and patient retention?
• What is your informed consent and clinical documentation? Can you demonstrate that patients are appropriately screened and monitored?

Practices with clear answers to all four of these questions clear at higher multiples than practices with vague answers. The variation is not subtle — it can be 1–2 turns of EBITDA on the weight loss revenue line.

How Weight-Loss Revenue Enters Valuation

No primary public source substantiates fixed 2026 EBITDA ranges for GLP-1 clinics. Buyers must evaluate normalized earnings, branded-versus-compounded exposure, patient retention, provider continuity, sourcing, documentation, owner dependence, and deal structure using current clinic-specific evidence.

The buyer universe for weight loss practices

Four buyer types are active in this segment:

1. Med spa platforms with existing weight loss programs. Practices like Princeton MedSpa Partners, AYA Medical Spa, and similar PE-backed builders are tucking in weight loss-anchored practices to extend their existing programs. Multiples are competitive, integration is fast.

2. Dedicated weight loss platforms. A small number of newer PE-backed platforms have built specifically around medical weight loss. These buyers pay the highest multiples for platform-quality weight loss businesses.

3. Telehealth weight loss companies. Hims, Ro, Found, and other telehealth-first weight loss companies have looked at acquiring in-person practices to address clinical supervision requirements, scope-of-practice issues, and patient retention challenges. This buyer category is the wildcard — these companies have sometimes paid above-market multiples for in-person practices that provide regulatory cover and patient grounding.

4. Dermatology and aesthetic groups. Several dermatology and aesthetic platforms have added weight loss as a service line via acquisition. Multiples are slightly below dedicated weight loss platforms but the buyer pool is broader.

The job of running an auction is to put as many of these buyer types as possible into the same room.

What the GLP-1 era has changed about how to position a med spa for sale

If your practice has a weight loss program — whether it’s the dominant revenue line or a 20% adjacency — the way you position it for buyers matters. Three principles:

1. Document the patient cohort. Buyers want to see the cohort data. Who started a GLP-1 program when. Who is still active. What the average revenue per active patient is. What the churn curve looks like at 6, 12, and 18 months. Practices that have this data ready clear at premium multiples. Practices that present trailing twelve months revenue without cohort detail get repriced at diligence.

2. Document the compliance posture. Compounding sourcing documentation, state-by-state prescribing protocols, NP/PA scope of practice documentation, lab monitoring records, informed consent protocols. All of this gets organized in the data room before buyers see anything. Buyers price documented compliance much higher than undocumented compliance, even when the underlying practice is the same.

3. Document the provider model. How does the practice scale? What does the provider model look like? What is the supervisory structure? How can a buyer extend the model into new geographies? A practice that has answered these questions in writing presents a growth narrative; a practice that hasn’t presents a steady-state.

What hasn’t changed

A few things buyers don’t care about as much as some owners think:

Brand recognition in the local market. Local brand matters less than retention curves. Buyers will gladly rebrand a practice with strong unit economics under their platform identity.

Whether you “got in early” on GLP-1s. Buyers underwrite the current cohort, not the historical narrative. A practice that started its GLP-1 program in 2024 with strong retention is worth more than a practice that started in 2022 with weak retention.

Marketing channel mix. As long as patient acquisition cost is reasonable, buyers don’t care whether patients come from paid digital, organic, word of mouth, or cross-referral. They care that the model is reproducible.

Frequently asked questions

Should I sell my weight loss practice now or wait for more clarity in the GLP-1 market?

Timing depends on the clinic’s financial quality, FDA and state-law exposure, sourcing model, provider continuity, patient retention, and the owner’s objectives. Buyer competition and multiples should not be described as predictably stronger now without current, identifiable transaction evidence.

What if I’m using compounded GLP-1s and the regulatory landscape changes?

Buyers price this risk. They will ask for your sourcing documentation, your transition plan, and your cost structure under both scenarios (compounded continues, compounded narrows). Practices with thoughtful answers to all three questions clear at acceptable multiples even in the face of regulatory uncertainty. The wrong move is to ignore the question and hope buyers won’t ask — they will, and “I don’t know” gets repriced.

How much weight loss revenue do I need before it becomes a meaningful value driver?

There is no universal revenue threshold. Materiality depends on contribution margin, patient retention, sourcing exposure, provider dependence, documentation, and how the revenue affects the clinic’s overall risk and transferability.

Are buyers worried about the long-term sustainability of GLP-1 demand?

Some are. The buyers actively buying right now are doing so because they believe the patient base, the retention curve, and the broader cash-pay weight loss demand will outlast any single drug or pricing dynamic. The auction process self-selects for buyers who have a thesis on the segment.

• Sell a Medical Weight Loss Practice
• Med Spa Membership Revenue: How Recurring Revenue Affects Your Valuation
• What Med Spa Buyers Actually Look For
• Med Spa EBITDA Multiples: 2026 Market Data